November 3, 2015
Faron Pharmaceuticals secures Clevegen production with Swiss Selexis
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.